Walleye Capital LLC Purchases New Position in Unicycive Therapeutics, Inc. (NASDAQ:UNCY)

Walleye Capital LLC acquired a new position in shares of Unicycive Therapeutics, Inc. (NASDAQ:UNCY) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 5,000,000 shares of the company’s stock, valued at approximately $2,040,000. Walleye Capital LLC owned approximately 0.05% of Unicycive Therapeutics at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. Acuta Capital Partners LLC bought a new stake in shares of Unicycive Therapeutics in the 3rd quarter worth about $807,000. Great Point Partners LLC acquired a new position in Unicycive Therapeutics in the third quarter valued at about $3,491,000. Bleakley Financial Group LLC bought a new stake in Unicycive Therapeutics during the third quarter worth about $33,000. Finally, Virtu Financial LLC bought a new stake in Unicycive Therapeutics during the first quarter worth about $36,000. 40.42% of the stock is currently owned by institutional investors and hedge funds.

Unicycive Therapeutics Stock Down 3.3 %

Shares of NASDAQ UNCY opened at $0.71 on Wednesday. Unicycive Therapeutics, Inc. has a 1-year low of $0.20 and a 1-year high of $1.82. The company has a 50-day moving average of $0.47 and a two-hundred day moving average of $0.50.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the stock. Benchmark reiterated a “speculative buy” rating and issued a $3.00 target price on shares of Unicycive Therapeutics in a research note on Friday, November 22nd. HC Wainwright reiterated a “buy” rating and issued a $2.50 price objective on shares of Unicycive Therapeutics in a research report on Tuesday, November 12th. Four equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Buy” and an average target price of $5.13.

Unicycive Therapeutics Company Profile

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.